|
|
|
Insider
Information: |
Mott David M |
Relationship: |
Director |
City: |
Gaithersburg |
State: |
MD |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
36 |
|
Direct
Shares |
6,113,369 |
|
Indirect Shares
|
266,283,930 |
|
|
Direct
Value |
$9,566,410 |
|
|
Indirect Value
|
$978,680,242 |
|
|
Total
Shares |
272,397,299 |
|
|
Total
Value |
$988,246,651 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
10
|
0
|
Stock
price went up :
|
4
|
0
|
Stock
price went down : |
6
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
23.6%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Medimmune Inc |
MEDI |
Vice Chairman, CEO & P... |
2007-06-01 |
0 |
2003-09-15 |
0 |
Premium* |
|
Clovis Oncology, Inc. |
CLVS |
10% Owner |
2011-11-21 |
0 |
2013-06-03 |
575 |
Premium* |
|
Millennial Media Inc |
MM |
10% Owner |
2012-04-03 |
0 |
2012-10-29 |
8,196,614 |
Premium* |
|
Tesaro, Inc. |
TSRO |
Director, 10% Owner |
2019-01-22 |
0 |
2019-01-22 |
0 |
Premium* |
|
Workday, Inc. |
WDAY |
10% Owner |
2013-04-09 |
0 |
2013-04-09 |
1,171 |
Premium* |
|
Interleukin Genetics Inc |
ILIU |
10% Owner |
|
0 |
2016-07-29 |
55,418,811 |
Premium* |
|
Epizyme, Inc. |
EPZM |
Director |
2022-08-12 |
0 |
2022-08-12 |
0 |
Premium* |
|
Care.com Inc |
CRCM |
10% Owner |
2014-01-29 |
0 |
2017-11-06 |
2,302 |
Premium* |
|
Roka Bioscience, Inc. |
ROKA |
10% Owner |
|
0 |
2014-07-22 |
3,216,810 |
Premium* |
|
Loxo Oncology, Inc. |
LOXO |
10% Owner |
2014-08-06 |
0 |
2014-08-06 |
1,789,420 |
Premium* |
|
Box Inc |
BOX |
10% Owner |
|
0 |
2015-01-28 |
0 |
Premium* |
|
Tracon Pharmaceuticals, Inc. |
TCON |
10% Owner |
2015-02-04 |
0 |
2016-11-29 |
2,758,039 |
Premium* |
|
Champions Biotechnology Inc |
CSBR |
10% Owner |
|
0 |
2015-03-11 |
18,750,000 |
Premium* |
|
Ardelyx Inc |
ARDX |
Director |
2023-06-15 |
1,192,275 |
2019-12-09 |
6,564,372 |
Premium* |
|
Nuvelo Inc |
ABIO |
10% Owner |
|
0 |
2018-02-26 |
0 |
Premium* |
|
Synlogic Inc |
SYBX |
10% Owner |
2015-10-05 |
0 |
2018-01-26 |
4,228,940 |
Premium* |
|
Avalo Therapeutics, Inc |
AVTX |
10% Owner |
2015-10-20 |
0 |
2015-10-20 |
594,245 |
Premium* |
|
Adaptimmune Therapeutics PLC |
ADAP |
Director, 10% Owner |
|
0 |
2020-01-24 |
102,478,668 |
Premium* |
|
Aveo Pharmaceuticals Inc |
AVEO |
10% Owner |
|
0 |
2019-04-08 |
25,243,865 |
Premium* |
|
Achaogen Inc |
AKAO |
10% Owner |
|
0 |
2016-12-19 |
5,215,128 |
Premium* |
|
Ra Pharmaceuticals, Inc. |
RARX |
10% Owner |
2016-10-31 |
0 |
2016-10-31 |
3,490,073 |
Premium* |
|
Cascadian Therapeutics, Inc |
CASC |
10% Owner |
|
0 |
2018-03-09 |
0 |
Premium* |
|
Mulesoft, Inc |
MULE |
10% Owner |
|
0 |
2018-05-01 |
0 |
Premium* |
|
Mersana Therapeutics, Inc. |
MRSN |
Director |
2024-01-02 |
588,694 |
2024-01-02 |
9,595 |
Premium* |
|
Regulus Therapeutics Inc. |
RGLS |
10% Owner |
|
0 |
2019-05-07 |
2,052,454 |
Premium* |
|
Surface Oncology, Inc. |
SURF |
10% Owner |
2018-04-23 |
0 |
2018-04-23 |
3,312,877 |
Premium* |
|
Rhythm Pharmaceuticals, Inc. |
RYTM |
10% Owner |
2017-10-10 |
0 |
2017-10-10 |
4,909,956 |
Premium* |
|
Appian Corp |
APPN |
10% Owner |
2017-11-20 |
0 |
2018-02-13 |
2,031 |
Premium* |
|
Elastic N.v. |
ESTC |
10% Owner |
2018-10-10 |
0 |
2018-10-10 |
2,197,503 |
Premium* |
|
Genocea Biosciences, Inc. |
GNCA |
10% Owner |
2019-02-14 |
0 |
2019-06-24 |
7,225,676 |
Premium* |
|
Trevi Therapeutics, Inc. |
TRVI |
10% Owner |
2019-05-09 |
0 |
2019-05-09 |
4,438,562 |
Premium* |
|
Nightstar Therapeutics Plc |
NITE |
Director, 10% Owner |
2019-06-07 |
0 |
2019-06-07 |
0 |
Premium* |
|
Mirum Pharmaceuticals, Inc. |
MIRM |
10% Owner |
2019-07-22 |
0 |
2019-07-22 |
4,186,243 |
Premium* |
|
Cloudflare, Inc. |
NET |
10% Owner |
2019-09-17 |
4,059,376 |
2019-09-17 |
0 |
Premium* |
|
Novavax Inc |
NVAX |
Director |
2023-06-10 |
43,800 |
|
0 |
Premium* |
|
Enliven Therapeutics Ord Shs |
ELVN |
Director |
2022-02-23 |
229,224 |
2022-02-10 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
221 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 5 of 9
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ELVN |
Enliven Therapeutics Ord ... |
Director |
|
2022-02-22 |
4 |
B |
$1.56 |
$102,675 |
D/D |
65,817 |
193,967 |
2.39 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2020-06-18 |
4 |
A |
$0.00 |
$0 |
I/I |
67,662 |
106,959 |
0 |
- |
|
TSRO |
Tesaro, Inc. |
Director |
|
2018-03-02 |
4 |
B |
$54.32 |
$3,795,185 |
I/I |
68,302 |
724,089 |
2.25 |
- |
|
ARDX |
Ardelyx Inc |
Director |
|
2020-06-25 |
4 |
B |
$6.96 |
$476,040 |
D/D |
68,373 |
247,284 |
2.39 |
% |
|
AVEO |
Aveo Pharmaceuticals Inc |
10% Owner |
|
2018-05-08 |
4 |
B |
$2.13 |
$151,250 |
I/I |
70,873 |
17,354,543 |
1.5 |
- |
|
AVEO |
Aveo Pharmaceuticals Inc |
10% Owner |
|
2018-11-30 |
4 |
B |
$1.98 |
$142,067 |
I/I |
71,900 |
20,164,438 |
1.5 |
- |
|
ARDX |
Ardelyx Inc |
Director |
|
2020-06-24 |
4 |
B |
$6.75 |
$489,862 |
D/D |
72,598 |
178,911 |
2.39 |
% |
|
RARX |
Ra Pharmaceuticals, Inc. |
10% Owner |
|
2016-10-31 |
4 |
OE |
$0.07 |
$5,646 |
I/I |
80,658 |
80,658 |
0 |
- |
|
MEDI |
Medimmune Inc |
Vice Chairman, CEO & President |
|
2007-03-19 |
4 |
OE |
$7.40 |
$765,900 |
D/D |
103,500 |
422,116 |
0 |
- |
|
ADAP |
Adaptimmune Therapeutics ... |
Director |
|
2018-03-21 |
4 |
B |
$1.81 |
$189,820 |
I/I |
104,844 |
72,243,844 |
2.25 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2022-08-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(106,959) |
0 |
0 |
- |
|
MEDI |
Medimmune Inc |
Vice Chairman, CEO & President |
|
2006-12-06 |
4 |
OE |
$2.46 |
$268,756 |
D/D |
109,326 |
318,616 |
0 |
- |
|
AVEO |
Aveo Pharmaceuticals Inc |
10% Owner |
|
2018-12-07 |
4 |
B |
$1.98 |
$232,362 |
I/I |
117,100 |
20,308,838 |
1.5 |
- |
|
MEDI |
Medimmune Inc |
Vice Chairman, CEO & President |
|
2007-03-23 |
4 |
OE |
$7.40 |
$957,479 |
D/D |
129,389 |
605,098 |
0 |
- |
|
SURF |
Surface Oncology, Inc. |
10% Owner |
|
2018-04-23 |
4 |
B |
$15.00 |
$1,999,995 |
I/I |
133,333 |
3,312,877 |
1.5 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2019-06-24 |
4/A |
A |
$0.00 |
$0 |
I/I |
165,919 |
8,502 |
0 |
- |
|
AVEO |
Aveo Pharmaceuticals Inc |
10% Owner |
|
2018-11-20 |
4 |
B |
$1.98 |
$336,107 |
I/I |
170,000 |
20,068,038 |
1.5 |
- |
|
ARDX |
Ardelyx Inc |
Director |
|
2020-12-10 |
4 |
B |
$5.89 |
$1,000,841 |
D/D |
170,000 |
417,284 |
2.39 |
% |
|
ARDX |
Ardelyx Inc |
Director |
|
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
182,481 |
599,765 |
0 |
- |
|
AVEO |
Aveo Pharmaceuticals Inc |
10% Owner |
|
2018-05-17 |
4 |
B |
$2.13 |
$391,436 |
I/I |
184,179 |
17,538,722 |
1.5 |
- |
|
AVEO |
Aveo Pharmaceuticals Inc |
10% Owner |
|
2018-06-28 |
4 |
B |
$2.10 |
$392,692 |
I/I |
187,130 |
17,783,722 |
1.5 |
- |
|
EPZM |
Epizyme, Inc. |
Director |
|
2017-09-18 |
4 |
B |
$15.25 |
$3,050,000 |
I/I |
200,000 |
6,054,351 |
2.1 |
- |
|
AVEO |
Aveo Pharmaceuticals Inc |
10% Owner |
|
2018-07-18 |
4 |
B |
$1.95 |
$390,580 |
I/I |
200,000 |
17,983,722 |
1.5 |
- |
|
AVEO |
Aveo Pharmaceuticals Inc |
10% Owner |
|
2018-12-20 |
4 |
B |
$1.63 |
$326,060 |
I/I |
200,000 |
20,596,038 |
1.5 |
- |
|
AVEO |
Aveo Pharmaceuticals Inc |
10% Owner |
|
2018-04-10 |
4 |
B |
$2.46 |
$499,994 |
I/I |
203,200 |
17,283,670 |
1.5 |
- |
|
221 Records found
|
|
Page 5 of 9 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|